Physician profile
Robert Cody
NPI 1295721215
$593.58
in general payments reported to CMS, 2019-2025
15 companies · $45.80 in 2025
The $45.80 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $36.35 · 2021: $23.81 · 2022: $128 · 2023: $129 · 2024: $64.57 · 2025: $45.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201 · Education: $38.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.61 |
| Education | $38.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $91.83 | 2019-2023 | Phesgo, Perjeta |
| Pfizer INC. | $75.80 | 2019-2022 | |
| Incyte Corporation | $64.57 | 2024 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $62.93 | 2020-2023 | Reblozyl, Opdivo |
| Exelixis INC. | $45.80 | 2025 | Cabometyx |
| Foundation Medicine, INC. | $38.88 | 2019 | |
| Genzyme Corporation | $38.49 | 2022 | |
| Spectrum Pharmaceuticals INC. | $29.95 | 2023 | Rolvedon |
| Takeda Pharmaceuticals U.S.A., INC. | $29.93 | 2022 | |
| Tactile Systems Technology INC | $29.47 | 2023 | Entre Plus, Flexitouch Plus |
| Pharmacyclics LLC, An Abbvie Company | $25.44 | 2019 | |
| Janssen Biotech, INC. | $23.60 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.